A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis

The goal of this study is to find out if a medication called upadacitinib can help treat a condition called Eosinophilic Esophagitis (EoE). This study has different parts. In the first part of the study, some people get the real medicine and some people get a "placebo," which is a pill with no medicine in it. These groups are decided by chance. In the second part of the study, everyone gets the real medication. After screening, qualified participants will be randomly assigned to receive either the medicine or placebo and start taking the medicine. Participants will come to the clinic for a visit every 4 weeks and have a physical exam, blood tests, answer health questions, and complete surveys. The first 12-weeks of the study treatment are "blinded," meaning participants and the study team won't know who gets the real medicine and who gets the placebo. The next 12 weeks are "open-label," meaning everyone gets upadacitinib. After each 12-week part, participants will have an upper endoscopy (esophagogastroduodenoscopy; EGD) to check on EoE disease activity. 30 days after the final EGD, participants will have a final checkup.